100 related articles for article (PubMed ID: 3677298)
1. Acetylation and oxidation phenotypes in malignant lymphoma.
Philip PA; Rogers HJ; Harper PG
Cancer Chemother Pharmacol; 1987; 20(3):235-8. PubMed ID: 3677298
[TBL] [Abstract][Full Text] [Related]
2. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
Horai Y; Fujita K; Ishizaki T
Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
4. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.
Edstein MD; Shanks GD; Teja-Isavadharm P; Rieckmann KH; Webster HK
Br J Clin Pharmacol; 1994 Jan; 37(1):67-70. PubMed ID: 8148220
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Wiela-Hojeńska A; Milejski P; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Urbaniak-Kujda D; Kotlarek-Haus S
Przegl Lek; 1997; 54(3):163-6. PubMed ID: 9297191
[TBL] [Abstract][Full Text] [Related]
6. N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.
Siegmund W; Hanke W; Zschiesche M; Franke G; Biebler KE; Wilke A
Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):504-9. PubMed ID: 2086491
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic debrisoquin metabolism in a Turkish population.
Bozkurt A; Basci NE; Isimer A; Sayal A; Kayaalp SO
Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin malignant lymphomas and Hodgkin's disease in first-degree relatives. Evidence for a mutual genetic predisposition?
Bjerrum OW; Hasselbalch HC; Drivsholm A; Nissen NI
Scand J Haematol; 1986 Apr; 36(4):398-401. PubMed ID: 3715408
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquin oxidation polymorphism in a Spanish population.
Benítez J; LLerena A; Cobaleda J
Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.
Bradley SV; Smith MR; Hyun TS; Lucas PC; Li L; Antonuk D; Joshi I; Jin F; Ross TS
Cancer Res; 2007 Sep; 67(18):8923-31. PubMed ID: 17875735
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma.
Crossen PE; Morrison MJ; Colls BM
Br J Cancer; 1994 Apr; 69(4):759-61. PubMed ID: 7908219
[TBL] [Abstract][Full Text] [Related]
12. Influence of age, sex and body weight on the dapsone acetylation phenotype.
Philip PA; Gayed SL; Rogers HJ; Crome P
Br J Clin Pharmacol; 1987 Jun; 23(6):709-13. PubMed ID: 3606931
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of chylomicron-like emulsions in patients with Hodgkin's and with non-Hodgkin's lymphoma.
Gonçalves RP; Hungria VT; Chiattone CS; Pozzi DB; Maranhão RC
Leuk Res; 2003 Feb; 27(2):147-53. PubMed ID: 12526920
[TBL] [Abstract][Full Text] [Related]
14. The disposition of dapsone in cirrhosis.
May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
[TBL] [Abstract][Full Text] [Related]
15. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
[TBL] [Abstract][Full Text] [Related]
17. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
18. Familial lymphoma: review of the literature and report of two brothers with lymphosarcoma.
MALDONADO N; LEVIN M
Bol Asoc Med P R; 1961 Sep; 53():325-37. PubMed ID: 14468845
[No Abstract] [Full Text] [Related]
19. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma.
Cunningham LM; Chapman C; Dunstan R; Bell MC; Joske DJ
Leuk Lymphoma; 2003 Feb; 44(2):251-5. PubMed ID: 12688341
[TBL] [Abstract][Full Text] [Related]
20. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
